SCHEMBL3534447

SCHEMBL3534447

Cn1[c]nc(-c2ncc[nH]2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.40
NISCH Q9Y2I1 2/20 0.38
MTOR P42345 1/20 0.36
ADK P55263 1/20 0.36
ALDH1A1 P00352 4/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SMPD3 Q9NY59 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP19A1 P11511 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
PDE3B Q13370 1/20 0.31
PDE3A Q14432 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14837491 0.72 CSNK1A1 (0.40) BRD4NISCHMTORADKALDH1A1
SCHEMBL7494587 0.70 BRD4 (0.45) BRD4NISCHMTORADKALDH1A1
SCHEMBL14401096 0.67 NISCH (0.44) BRD4NISCHMTORADKALDH1A1
SCHEMBL81650 0.66 NISCH (0.59) BRD4NISCHMTORADKALDH1A1
SCHEMBL21241220 0.64 BRD4 (0.46) BRD4NISCHMTORADKALDH1A1
SCHEMBL973075 0.64 NISCH (0.39) NISCHMTORADKALDH1A1SMN1; SMN2
SCHEMBL409012 0.64 NISCH (0.44) NISCHMTORADKALDH1A1SMN1; SMN2
SCHEMBL28425230 0.63 NISCH (0.56) BRD4NISCHMTORADKALDH1A1
Hydrochloric Acid SCHEMBL1536214 0.63 NISCH (0.56) BRD4NISCHMTORADKALDH1A1
SCHEMBL5491437 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES BRD4 3471/4885NISCH 4206/4885MTOR 1446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.